Literature DB >> 23686309

The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells.

R Koyama-Nasu1, R Haruta1, Y Nasu-Nishimura1, K Taniue1, Y Katou2, K Shirahige2, T Todo3, Y Ino3, A Mukasa3, N Saito3, M Matsui1, R Takahashi1, A Hoshino-Okubo1, H Sugano1, E Manabe1, K Funato1, T Akiyama1.   

Abstract

Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin are required for the self-renewal and tumorigenicity of glioblastoma stem cells (GSCs). Furthermore, we demonstrate that pleiotrophin is transactivated directly by SOX2, a transcription factor essential for the maintenance of both neural stem cells and GSCs. We speculate that the pleiotrophin-ALK axis may be a promising target for the therapy of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686309     DOI: 10.1038/onc.2013.168

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.

Authors:  Anne Berberich; Lara-Marie Schmitt; Stefan Pusch; Thomas Hielscher; Petra Rübmann; Nanina Hucke; Pauline Latzer; Bernd Heßling; Dieter Lemke; Tobias Kessler; Michael Platten; Wolfgang Wick
Journal:  J Neurooncol       Date:  2019-11-28       Impact factor: 4.130

2.  The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).

Authors:  Kenji Tsuchihashi; Shogo Okazaki; Mitsuyo Ohmura; Miyuki Ishikawa; Oltea Sampetrean; Nobuyuki Onishi; Hiroaki Wakimoto; Momoko Yoshikawa; Ryo Seishima; Yoshimi Iwasaki; Takayuki Morikawa; Shinya Abe; Ayumi Takao; Misato Shimizu; Takashi Masuko; Motoo Nagane; Frank B Furnari; Tetsu Akiyama; Makoto Suematsu; Eishi Baba; Koichi Akashi; Hideyuki Saya; Osamu Nagano
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

3.  Expression of SOX2 in oral squamous cell carcinoma and the association with lymph node metastasis.

Authors:  Zhen-Hu Ren; Chen-Ping Zhang; Tong Ji
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

4.  Integrative Network Analysis Combined with Quantitative Phosphoproteomics Reveals Transforming Growth Factor-beta Receptor type-2 (TGFBR2) as a Novel Regulator of Glioblastoma Stem Cell Properties.

Authors:  Yuta Narushima; Hiroko Kozuka-Hata; Ryo Koyama-Nasu; Kouhei Tsumoto; Jun-ichiro Inoue; Tetsu Akiyama; Masaaki Oyama
Journal:  Mol Cell Proteomics       Date:  2015-12-15       Impact factor: 5.911

Review 5.  ALK-driven tumors and targeted therapy: focus on crizotinib.

Authors:  Carlos Murga-Zamalloa; Megan S Lim
Journal:  Pharmgenomics Pers Med       Date:  2014-03-20

Review 6.  Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.

Authors:  Niki Karachaliou; Rafael Rosell
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

7.  Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer.

Authors:  Youn Hee Jee; Samira M Sadowski; Francesco S Celi; Liqiang Xi; Mark Raffeld; David B Sacks; Alan T Remaley; Anton Wellstein; Electron Kebebew; Jeffrey Baron
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

Review 8.  Targeting Autophagy in ALK-Associated Cancers.

Authors:  Julie Frentzel; Domenico Sorrentino; Sylvie Giuriato
Journal:  Cancers (Basel)       Date:  2017-11-27       Impact factor: 6.639

9.  Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein.

Authors:  Dapeng Wu; Liguo Liu; Xuebing Yan; Chunyan Wang; Yaling Wang; Kun Han; Shuchen Lin; Zhihua Gan; Daliu Min
Journal:  Oncotarget       Date:  2017-07-10

Review 10.  Expression of sex-determining region Y-box protein 2 in breast cancer and its clinical significance.

Authors:  Xuesong Feng; Mingqian Lu
Journal:  Saudi Med J       Date:  2017-07       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.